Draft:HemoHIM
Submission declined on 19 January 2025 by DoubleGrazing (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies. This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
| ![]() |
![](http://upload.wikimedia.org/wikipedia/commons/thumb/3/3b/HemoHIM.jpg/220px-HemoHIM.jpg)
HemoHIM
HemoHIM is a herbal dietary supplement developed in South Korea. It is marketed by Atomy Corporation.
History and Development
HemoHIM was developed by Kolmar BNH, a joint venture between Kolmar Korea and the Korea Atomic Energy Research Institute (KAERI), with funding from the South Korean government. Research began in 1997 at KAERI's Food Science Biotechnology Team. The initial goal was to strengthen the immune systems of researchers exposed to radiation in their work on nuclear energy.
After eight years of research, the HemoHIM compound was formulated in 2002. It is composed of extracts from three traditional Korean plants:
- Angelica gigas Nakai (Korean giant angelica)
- Cnidium officinale Makino (Cnidium officinale)
- Paeonia japonica Miyabe (Japanese peony)
The development process consisted of optimizing the extraction and combination of active compounds from these plants to create a standardized compound. In 2006, HemoHIM received approval from the Korean Ministry of Food and Drug Safety (MFDS).
Studies and Claims
Several studies have been conducted on HemoHIM, some of which have been published in scientific journals.
These studies explore the potential effects of HemoHIM on a variety of aspects, including:
- Natural Killer (NK) cell activity: Studies suggest that HemoHIM may stimulate the activity of these cells, which play an important role in the immune system.
- Cytokine production: Research has examined the influence of HemoHIM on the production of certain cytokines, signaling molecules involved in communication between immune cells.
- Fatigue reduction: Studies have been conducted in specific populations, such as cancer patients undergoing chemotherapy or elderly women, suggesting a possible reduction in fatigue.
It is important to note that the majority of these studies were conducted in vitro (in the laboratory) or in animal models. Larger and more rigorous clinical studies in human populations are needed to fully confirm these results and establish the clinical efficacy of HemoHIM.
Regulatory status and safety
HemoHIM is classified as a dietary supplement in many countries. In South Korea, it was the first dietary supplement to receive individual approval for its effect on improving immune function. It has also obtained certifications from other regulatory agencies, including the FDA in the United States.
Like any dietary supplement, HemoHIM may potentially interact with medications or be contraindicated in certain situations. It is therefore recommended to consult a health professional before starting its consumption, particularly in case of pre-existing health conditions or taking medications. Vigilance is also required regarding counterfeits.
References and sources
- Kim, B. K., et al. (2004). Immunomodulatory activity of a herbal preparation (HemoHIM) on natural killer cell activity in cancer patients. Immunopharmacology and immunotoxicology, 26(4), 519-535.
- Park, H. Y., et al. (2009).Radioprotective effect of HemoHIM in mice. Journal of medicinal foods, 12(2), 260-265.
- Song, G. Y., et al. (2003). HemoHIM enhances the production of Th1 cytokines and IFN-γ in mouse splenocytes. Journal of ethnopharmacology, 88(2-3), 263-269.
-Jo, S.K., et al. (2010).Effect of HemoHIM on fatigue in cancer patients undergoing chemotherapy. Korean journal of oriental physiology & pathology, 24(5), 819-824.
- Kim, H.J., et al. (2012).The effect of HemoHIM on fatigue and sleep quality in elderly women. Journal of Korean Academy of Nursing, 42(4), 541-550.
- Choi, E. M., et al. (2017). HemoHIM, a herbal preparation, alleviates airway inflammation caused by cigarette smoke and lipopolysaccharide. BMC complementary and alternative medicine, 17(1), 1-9.
https://mt.atomy.com/content/18?lang=en
https://thesun.my/spotlight/atomy-hemohim-developed-for-better-health-AM9529299
https://pubmed.ncbi.nlm.nih.gov/?term=HemoHim&sort
https://scholar.google.fr/scholar?hl=fr&as_sdt=0%2C5&q=HemoHIM&btnG=